Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?-Reference-Cited by-同舟云学术

Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?

Published:2021-07 Issue: Volume:89 Page:27-29
ISSN:0953-6205
Container-title:European Journal of Internal Medicine
language:en
Short-container-title:European Journal of Internal Medicine

Author:

van Erpecum Karel J.^ORCID,Sonneveld Milan J.

Funder

Gilead Sciences

Fujirebio Europe

Bristol-Myers Squibb

Roche

Publisher

Elsevier BV

Subject

Internal Medicine

Reference18 articles.

1. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010;Lozano;Lancet,2012

2. Trends in incidence, diagnosis, treatment and survival of hepatocellular carcinoma in a low-incidence country: data from the Netherlands in the period 2009–2016;Reinders;Eur J Cancer,2020

3. Early and late recurrence of hepatitis B virus-associated hepatocellular carcinoma;Wang;Oncologist,2020

4. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma;Chan;Arch Surg,2011

5. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection;Wu;JAMA - J Am Med Assoc,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is tenofovir disoproxil fumarate superior to entecavir for prevention of hepatocellular carcinoma in patients with chronic hepatitis B?;Hepatobiliary Surgery and Nutrition;2023-12

2. Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma;European Journal of Internal Medicine;2022-09